About Glutamate receptor ionotropic, delta-2
Glutamate receptor ionotropic, delta-2 (GRID2) is a protein
from Homo sapiens identified by UniProt accession
O43424, 1007 residues long.
MolForge cross-references it against 0 known binders and
614 disease associations.
Target properties
| Protein name | Glutamate receptor ionotropic, delta-2 |
|---|
| UniProt accession | O43424 |
|---|
| Gene | GRID2 |
|---|
| Organism | Homo sapiens |
|---|
| Length | 1007 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (614)
Diseases linked to this target (Open Targets).
- Autosomal recessive congenital cerebellar ataxia due to GRID2 deficiency · score 0.68
- autosomal recessive spinocerebellar ataxia 18 · score 0.62
- genetic disorder · score 0.47
- neurodegenerative disease · score 0.45
- cerebellar ataxia · score 0.37
- cognitive function measurement · score 0.34
- traffic air pollution measurement · score 0.30
- body mass index · score 0.28
- self reported educational attainment · score 0.26
- neuroinflammatory disorder · score 0.25
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-O43424-F1 | alphafold | PREDICTED | 75.88 | — |
Amino-acid sequence (1007 residues)
MEVFPFLLVL SVWWSRTWDS ANADSIIHIG AIFDESAKKD DEVFRTAVGD LNQNEEILQT EKITFSVTFV DGNNPFQAVQ EACELMNQGI LALVSSIGCT SAGSLQSLAD AMHIPHLFIQ RSTAGTPRSG CGLTRSNRND DYTLSVRPPV YLHDVILRVV TEYAWQKFII FYDSEYDIRG IQEFLDKVSQ QGMDVALQKV ENNINKMITT LFDTMRIEEL NRYRDTLRRA ILVMNPATAK SFITEVVETN LVAFDCHWII INEEINDVDV QELVRRSIGR LTIIRQTFPV PQNISQRCFR GNHRISSTLC DPKDPFAQNM EISNLYIYDT VLLLANAFHK KLEDRKWHSM ASLSCIRKNS KPWQGGRSML ETIKKGGVSG LTGELEFGEN GGNPNVHFEI LGTNYGEELG RGVRKLGCWN PVTGLNGSLT DKKLENNMRG VVLRVVTVLE EPFVMVSENV LGKPKKYQGF SIDVLDALSN YLGFNYEIYV APDHKYGSPQ EDGTWNGLVG ELVFKRADIG ISALTITPDR ENVVDFTTRY MDYSVGVLLR RAEKTVDMFA CLAPFDLSLW ACIAGTVLLV GLLVYLLNWL NPPRLQMGSM TSTTLYNSMW FVYGSFVQQG GEVPYTTLAT RMMMGAWWLF ALIVISSYTA NLAAFLTITR IESSIQSLQD LSKQTEIPYG TVLDSAVYEH VRMKGLNPFE RDSMYSQMWR MINRSNGSEN NVLESQAGIQ KVKYGNYAFV WDAAVLEYVA INDPDCSFYT IGNTVADRGY GIALQHGSPY RDVFSQRILE LQQNGDMDIL KHKWWPKNGQ CDLYSSVDTK QKGGALDIKS FAGVFCILAA GIVLSCFIAM LETWWNKRKG SRVPSKEDDK EIDLEHLHRR VNSLCTDDDS PHKQFSTSSI DLTPLDIDTL PTRQALEQIS DFRNTHITTT TFIPEQIQTL SRTLSAKAAS GFTFGNVPEH RTGPFRHRAP NGGFFRSPIK TMSSIPYQPT PTLGLNLGND PDRGTSI
Explore Glutamate receptor ionotropic, delta-2 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets